BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3602173)

  • 1. Predictive value of staging investigations in patients with clinical stage I malignant melanoma.
    Iscoe N; Kersey P; Gapski J; Osoba D; From L; DeBoer G; Quirt I
    Plast Reconstr Surg; 1987 Aug; 80(2):233-9. PubMed ID: 3602173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma.
    Kersey PA; Iscoe NA; Gapski JA; Osoba D; From L; DeBoer G; Quirt IC
    Br J Surg; 1985 Aug; 72(8):614-7. PubMed ID: 4027532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does staging computered tomography change management in thick malignant melanoma?
    Sawyer A; McGoldrick RB; Mackey SP; Allan R; Powell B
    J Plast Reconstr Aesthet Surg; 2009 Apr; 62(4):453-6. PubMed ID: 18468970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
    Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of staging workup in malignant melanoma.
    Khansur T; Sanders J; Das SK
    Arch Surg; 1989 Jul; 124(7):847-9. PubMed ID: 2742488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage I-II melanoma: the value of metastatic work-up.
    Ardizzoni A; Grimaldi A; Repetto L; Bruzzone M; Sertoli MR; Rosso R
    Oncology; 1987; 44(2):87-9. PubMed ID: 3574855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II.
    Klode J; Dissemond J; Grabbe S; Hillen U; Poeppel T; Boeing C
    Dermatol Surg; 2010 Apr; 36(4):439-45. PubMed ID: 20187901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification and staging of melanoma.
    Gershenwald JE; Buzaid AC; Ross MI
    Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline staging in cutaneous malignant melanoma.
    Hafner J; Schmid MH; Kempf W; Burg G; Künzi W; Meuli-Simmen C; Neff P; Meyer V; Mihic D; Garzoli E; Jungius KP; Seifert B; Dummer R; Steinert H
    Br J Dermatol; 2004 Apr; 150(4):677-86. PubMed ID: 15099363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma.
    Abdel-Rahman O
    Melanoma Res; 2019 Feb; 29(1):53-58. PubMed ID: 30362976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG PET in early stage cutaneous malignant melanoma.
    McIvor J; Siew T; Campbell A; McCarthy M
    J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
    Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
    J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of preoperative screening procedures in stage I and II malignant melanoma.
    Aranha GV; Simmons RL; Gunnarsson A; Grage TB; McKhann CF
    J Surg Oncol; 1979; 11(1):1-6. PubMed ID: 431076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
    Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
    Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular staging of malignant melanoma: correlation with clinical outcome.
    Shivers SC; Wang X; Li W; Joseph E; Messina J; Glass LF; DeConti R; Cruse CW; Berman C; Fenske NA; Lyman GH; Reintgen DS
    JAMA; 1998 Oct; 280(16):1410-5. PubMed ID: 9801000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sentinel lymph node in malignant melanoma].
    Rovenská E
    Vnitr Lek; 2014; 60(5-6):484-9. PubMed ID: 24974753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
    Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
    Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma?
    Cobben DC; Jager PL; Elsinga PH; Maas B; Suurmeijer AJ; Hoekstra HJ
    J Nucl Med; 2003 Dec; 44(12):1927-32. PubMed ID: 14660718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma staging: facts and controversies.
    Forschner A; Eigentler TK; Pflugfelder A; Leiter U; Weide B; Held L; Meier F; Garbe C
    Clin Dermatol; 2010; 28(3):275-80. PubMed ID: 20541679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging.
    Meyers MO; Yeh JJ; Frank J; Long P; Deal AM; Amos KD; Ollila DW
    Ann Surg Oncol; 2009 Apr; 16(4):941-7. PubMed ID: 19101766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.